-- complexities in designing and implementing cardiometabolic clinical trials using surrogate endpoints in Phase 1 and Phase 2 clinical trials which may differ from the ultimate endpoints required for registration of a candidate drug;
-- the results of our clinical trials, including without limitation, with respect to the safety and efficacy of VIA-2291;
-- if the results of the ACS and CEA studies, upon further review and analysis, are revised, interpreted differently by regulatory authorities or negated by later stage clinical trials;
-- our ability to obtain necessary FDA approvals, including to initiate future clinical trials of VIA-2291;
-- our ability to successfully commercialize VIA-2291;
-- our ability to identify potential clinical candidates from the family of DGAT1 compounds licensed and move them into preclinical development;
-- our ability to obtain and protect our intellectual property related to our product candidates;
-- our potential for future growth and the development of our product pipeline, including the THR beta agonist candidate and the other compounds licensed from Roche;
-- our ability to obtain strategic opportunities to partner and collaborate with large biotechnology or pharmaceutical companies to further develop VIA-2291;
-- our ability to form and maintain collaborative relationships to develop and commercialize our product candidates;
-- general economic and business conditions; and
-- the other risks described under Item 1A "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2008, as supplemented by the risks described under Item 1A "Risk Factors" in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2009, June 30, 2009, and September 30, 2009, each on file with the SEC.
|SOURCE VIA Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved